These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28721913)

  • 1. Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients.
    Kim KY; Le QT; Yom SS; Ng RHW; Chan KCA; Bratman SV; Welch JJ; Divi RL; Petryshyn RA; Conley BA
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):996-1001. PubMed ID: 28721913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer.
    Kim KY; Le QT; Yom SS; Pinsky BA; Bratman SV; Ng RH; El Mubarak HS; Chan KC; Sander M; Conley BA
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
    Fung SY; Lam JW; Chan KC
    Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
    Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
    Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Epstein-Barr virus microRNAs miR-BART7 and miR-BART13 as biomarkers for nasopharyngeal carcinoma diagnosis and treatment.
    Zhang G; Zong J; Lin S; Verhoeven RJ; Tong S; Chen Y; Ji M; Cheng W; Tsao SW; Lung M; Pan J; Chen H
    Int J Cancer; 2015 Mar; 136(5):E301-12. PubMed ID: 25213622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis.
    Liu TB; Zheng ZH; Pan J; Pan LL; Chen LH
    Clin Invest Med; 2017 Feb; 40(1):E1-E12. PubMed ID: 28218577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
    Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
    Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus.
    Fan H; Nicholls J; Chua D; Chan KH; Sham J; Lee S; Gulley ML
    Int J Cancer; 2004 Dec; 112(6):1036-41. PubMed ID: 15386346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma.
    Chen WH; Tang LQ; Zhang L; Chen QY; Guo SS; Liu LT; Fan W; Zhang X; Guo L; Zhao C; Cao KJ; Qian CN; Guo X; Xie D; Zeng MS; Mai HQ
    Oncotarget; 2015 Nov; 6(35):38296-307. PubMed ID: 26512922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
    Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
    PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study.
    Tang LQ; Li CF; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Chen WH; Liu H; Guo SS; Liu LT; Li J; Zhang JP; Guo L; Zhao C; Cao KJ; Qian CN; Zeng YX; Guo X; Mai HQ; Zeng MS
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):325-36. PubMed ID: 25482300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
    J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus DNA load in nasopharyngeal brushings and whole blood in nasopharyngeal carcinoma patients before and after treatment.
    Adham M; Greijer AE; Verkuijlen SA; Juwana H; Fleig S; Rachmadi L; Malik O; Kurniawan AN; Roezin A; Gondhowiardjo S; Atmakusumah D; Stevens SJ; Hermani B; Tan IB; Middeldorp JM
    Clin Cancer Res; 2013 Apr; 19(8):2175-86. PubMed ID: 23493345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
    Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
    Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma.
    Tang LQ; Li CF; Li J; Chen WH; Chen QY; Yuan LX; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Zhang L; Guo SS; Liu LT; Guo L; Wu YS; Luo DH; Huang PY; Mo HY; Xiang YQ; Sun R; Chen MY; Hua YJ; Lv X; Wang L; Zhao C; Cao KJ; Qian CN; Guo X; Zeng YX; Mai HQ; Zeng MS
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26467665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.
    Stoker SD; Wildeman MA; Novalic Z; Fles R; van der Noort V; de Bree R; Braunius WW; van den Broek GB; Kreike B; Kross KW; Juwana H; Ramayanti O; Verkuijlen SA; de Boer JP; Greijer AE; Middeldorp JM; Tan IB
    Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1557-67. PubMed ID: 25929413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.